MDXG MiMedx Group Inc.

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:

Craig-Hallum 16th Annual Alpha Select Conference | New York, NY

Tuesday, November 18, 2025

1:1 sessions

Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NY

Thursday, November 20, 2025

1:1 sessions

Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum or Canaccord representative.

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit .

Contact:

Matt Notarianni

Investor Relations

470-304-7291



EN
10/11/2025

Underlying

MDXGMiMedx Group Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX® Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the 15th anniversary of EPIFIX and AMNIOFIX, the Company’s placental allografts used in wound care and surgical recovery settings. “We are thrilled to mark the 15th anniversary of our flagship Wound and Surgical products, EPIFIX and AMNIOFIX, which have been instrumental to our pioneering innovatio...

February 2, 2026 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®...

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States. RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors,...

December 22, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Publication in the Journal of Inflammation Focused on...

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro Study investigates the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repair MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated human amnion chorion membrane (DHACM...

December 19, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”) Publication Adds to Large Compendium of Evidence for MIMEDX’s Leading Product Portfolio Trial Enrollment Ongoing MARIETTA, Ga., Nov. 13, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial (“RCT”) designed to...

November 13, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16th Annual Alpha Select Conference | New York, NYTuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NYThursday, November 20, 20251:1 sessions Investors interested in meeting with senior management at these events may contact their resp...

November 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch